2460539-61-9
2460539-61-9
Chemical Structure
Osemitamab
Synonym(s): TST001
- CAS No.: 2460539-61-9
- Formula:N/A
- Molecular Weight:(146.5 kDa)
SMILES: [Osemitamab]
Biological Activity: Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Osemitamab | 99.43% | Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002)[J]. 2023.
- [2]. Park Soon Jae, et al. Pharmaceutical composition comprising human hyaluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04.
